Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia
Launched by POITIERS UNIVERSITY HOSPITAL · Dec 28, 2023
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of a medication called Venetoclax for patients with Waldenström macroglobulinemia (WM), a type of blood cancer that currently has no cure. While previous research showed promising results with Venetoclax in treating WM, this study aims to gather real-life data from patients in France to better understand how well the drug works and how well patients tolerate it in everyday settings.
To participate in this study, individuals must have a diagnosis of Waldenström macroglobulinemia and be receiving treatment with Venetoclax. There are no age restrictions, and both men and women can join. Participants will be monitored for their responses to the treatment and any side effects they might experience. This research is important because it will help doctors learn more about how Venetoclax can be used to improve the lives of patients with WM in the real world.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Waldenstrom's macroglobulinemia
- • Treatment with Venetoclax
- • Non opposition
- • Exclusion Criteria: none
About Poitiers University Hospital
Poitiers University Hospital is a leading academic medical institution dedicated to advancing healthcare through innovative clinical research and trials. As a prominent sponsor of clinical studies, the hospital leverages its multidisciplinary expertise and state-of-the-art facilities to explore new therapeutic interventions and improve patient outcomes. With a commitment to ethical standards and patient safety, Poitiers University Hospital collaborates with healthcare professionals, researchers, and institutions to facilitate groundbreaking studies that contribute to medical knowledge and enhance treatment protocols across various specialties.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Poitiers, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported